3 Reasons Why Emergent Biosolutions (EBS) Is a Great Growth StockZacks Investment Research • 06/29/20
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy CapabilityGlobeNewsWire • 06/18/20
Emergent BioSolutions Will Manufacture AstraZeneca's COVID-19 Vaccine CandidateThe Motley Fool • 06/11/20
Emergent Biosolutions (EBS) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 06/11/20
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine CandidateGlobeNewsWire • 06/11/20
Emergent BioSolutions Picks Up a "Warp Speed" Contract to Manufacture Coronavirus VaccinesThe Motley Fool • 06/03/20
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and ManufacturingGlobeNewsWire • 06/01/20
Emergent Biosolutions (EBS) Up 12.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/30/20
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDTGlobeNewsWire • 05/07/20
Emergent Biosolutions CEO on Trump's wishes to develop a vaccine by year end — 'Nobody can guarantee anything'CNBC • 05/05/20
Emergent BioSolutions, Inc. (EBS) CEO Bob Kramer on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/02/20